Next Article in Journal
Improved Monitoring of Semi-Continuous Anaerobic Digestion of Sugarcane Waste: Effects of Increasing Organic Loading Rate on Methanogenic Community Dynamics
Next Article in Special Issue
Fingolimod (FTY720-P) Does Not Stabilize the Blood–Brain Barrier under Inflammatory Conditions in an in Vitro Model
Previous Article in Journal
Regulatory Proteolysis in Arabidopsis-Pathogen Interactions
Previous Article in Special Issue
Adaptive Immune Responses in a Multiple Sclerosis Patient with Acute Varicella-Zoster Virus Reactivation during Treatment with Fingolimod

Early and Degressive Putamen Atrophy in Multiple Sclerosis

Department of Neurology, Westfälische Wilhelms University, Albert-Schweitzer-Campus 1, Gebäude A1, 48149 Münster, Germany
Authors to whom correspondence should be addressed.
Academic Editor: Kurt A. Jellinger
Int. J. Mol. Sci. 2015, 16(10), 23195-23209;
Received: 28 May 2015 / Revised: 7 September 2015 / Accepted: 8 September 2015 / Published: 25 September 2015
(This article belongs to the Special Issue Advances in Multiple Sclerosis)
Putamen atrophy and its long-term progress during disease course were recently shown in patients with multiple sclerosis (MS). Here we investigated retrospectively the time point of atrophy onset in patients with relapsing-remitting MS (RRMS). 68 patients with RRMS and 26 healthy controls (HC) were admitted to 3T MRI in a cross-sectional study. We quantitatively analyzed the putamen volume of individual patients in relation to disease duration by correcting for age and intracranial volume (ICV). Patient’s relative putamen volume (RPV), expressed in percent of ICV, was significantly reduced compared to HC. Based on the correlation between RPV and age, we computed the age-corrected RPV deviation (ΔRPV) from HC. Patients showed significantly negative ΔRPV. Interestingly, the age-corrected ΔRPV depended logarithmically on disease duration: Directly after first symptom manifestation, patients already showed a reduced RPV followed by a further degressive volumetric decline. This means that atrophy progression was stronger in the first than in later years of disease. Putamen atrophy starts directly after initial symptom manifestation or even years before, and progresses in a degressive manner. Due to its important role in neurological functions, early detection of putamen atrophy seems necessary. High-resolution structural MRI allows monitoring of disease course. View Full-Text
Keywords: high-resolution structural MRI; FreeSurfer; volumetry; multiple sclerosis; early putamen atrophy; disease duration high-resolution structural MRI; FreeSurfer; volumetry; multiple sclerosis; early putamen atrophy; disease duration
Show Figures

Figure 1

MDPI and ACS Style

Krämer, J.; Meuth, S.G.; Tenberge, J.-G.; Schiffler, P.; Wiendl, H.; Deppe, M. Early and Degressive Putamen Atrophy in Multiple Sclerosis. Int. J. Mol. Sci. 2015, 16, 23195-23209.

AMA Style

Krämer J, Meuth SG, Tenberge J-G, Schiffler P, Wiendl H, Deppe M. Early and Degressive Putamen Atrophy in Multiple Sclerosis. International Journal of Molecular Sciences. 2015; 16(10):23195-23209.

Chicago/Turabian Style

Krämer, Julia, Sven G. Meuth, Jan-Gerd Tenberge, Patrick Schiffler, Heinz Wiendl, and Michael Deppe. 2015. "Early and Degressive Putamen Atrophy in Multiple Sclerosis" International Journal of Molecular Sciences 16, no. 10: 23195-23209.

Find Other Styles

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Back to TopTop